FMR LLC filed Amendment No. 13 to its Schedule 13G with the SEC on November 4, 2026, disclosing beneficial ownership of common stock in Ascendis Pharma A/S as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: FMR LLC reported beneficial ownership of 3,425,993.48 shares of Ascendis Pharma A/S common stock.
  • Percent of class: The reported holdings represent 5.2% of the outstanding common stock.
  • Sole voting power: FMR LLC holds sole voting power over 3,425,841.00 shares, with 0.00 shares subject to shared voting power.
  • Sole dispositive power: FMR LLC holds sole dispositive power over 3,425,993.48 shares, with 0.00 shares subject to shared dispositive power.
  • Abigail P. Johnson: Also named as a reporting person, she reports 0.00 sole voting power but sole dispositive power over the same 3,425,993.48 shares, also representing 5.2% of class.
  • Event date: The date of the event requiring this filing was September 30, 2026.

FMR LLC and Abigail P. Johnson Disclose Ownership Position in Ascendis Pharma A/S

According to the filing, FMR LLC, a Delaware-organized holding company located at 245 Summer Street, Boston, Massachusetts 02210, submitted Amendment No. 13 to its Schedule 13G regarding common stock of Ascendis Pharma A/S (CUSIP K08588103). The triggering event date is listed as September 30, 2026, and the statement was signed on November 4, 2026, by Stephanie J. Brown acting under a power of attorney on behalf of both FMR LLC and Abigail P. Johnson.

The filing reports that FMR LLC beneficially owns 3,425,993.48 shares, constituting 5.2% of the class. Of those shares, 3,425,841.00 are held with sole voting power and 3,425,993.48 with sole dispositive power. Abigail P. Johnson, identified as a U.S. citizen and a separate reporting person, reports the same aggregate beneficial ownership of 3,425,993.48 shares at 5.2%, with sole dispositive power over all such shares but no sole or shared voting power attributed to her individually.

The filing states under Item 6 that "one or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ASCENDIS PHARMA AS," but adds that "no one other person's interest in the COMMON STOCK of ASCENDIS PHARMA AS is more than five percent of the total outstanding COMMON STOCK." The filing also certifies, per Item 10, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

FMR LLC and Abigail P. Johnson filed Amendment No. 13 to Schedule 13G disclosing combined beneficial ownership of 3,425,993.48 shares, or 5.2%, of Ascendis Pharma A/S common stock as of September 30, 2026, with no shared voting or dispositive power reported.